CellMAC: a novel technology for encapsulation of mammalian cells in cellulose sulfate/pDADMAC capsules assembled on a transient alginate/Ca2+ scaffold

Weber, Wilfried; Rinderknecht, Matthias; Baba, Marie Daoud-El; Glutz, François-Nicolas de; Aubel, Dominique; Fussenegger, Martin

doi:10.1016/j.jbiotec.2004.07.014

Cited by 19 publications

(13 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These co-called ''CellMAC'' capsules, after dissolution of the alginate bead scaffold, proved to display excellent mechanical properties and cell viability. 139 Interestingly, permeability properties could be modified by adding inorganic salt or starch to the PE film. 151,152 Sefton and coworkers described a similar approach with PE methacrylate deposition on template alginate beads.…”

Section: Capsule Wall Formation By Pe Depositionmentioning

confidence: 99%

Progress technology in microencapsulation methods for cell therapy

Rabanel

Banquy

Zouaoui

et al. 2009

Biotechnology Progress

122

View full text Add to dashboard Cite

Cell encapsulation in microcapsules allows the in situ delivery of secreted proteins to treat different pathological conditions. Spherical microcapsules offer optimal surface-to-volume ratio for protein and nutrient diffusion, and thus, cell viability. This technology permits cell survival along with protein secretion activity upon appropriate host stimuli without the deleterious effects of immunosuppressant drugs. Microcapsules can be classified in 3 categories: matrix-core/shell microcapsules, liquid-core/shell microcapsules, and cells-core/shell microcapsules (or conformal coating). Many preparation techniques using natural or synthetic polymers as well as inorganic compounds have been reported. Matrix-core/shell microcapsules in which cells are hydrogel-embedded, exemplified by alginates capsule, is by far the most studied method. Numerous refinement of the technique have been proposed over the years such as better material characterization and purification, improvements in microbead generation methods, and new microbeads coating techniques. Other approaches, based on liquid-core capsules showed improved protein production and increased cell survival. But aside those more traditional techniques, new techniques are emerging in response to shortcomings of existing methods. More recently, direct cell aggregate coating have been proposed to minimize membrane thickness and implants size. Microcapsule performances are largely dictated by the physicochemical properties of the materials and the preparation techniques employed. Despite numerous promising pre-clinical results, at the present time each methods proposed need further improvements before reaching the clinical phase.

show abstract

Section: Capsule Wall Formation By Pe Depositionmentioning

confidence: 99%

Progress technology in microencapsulation methods for cell therapy

Rabanel

Banquy

Zouaoui

et al. 2009

Biotechnology Progress

122

View full text Add to dashboard Cite

show abstract

“…A key difference between the microencapsulation method presented here and those previously published (Simpson et al, 2003;Weber et al, 2004;Dusseault et al, 2005; and others) is cost-effectiveness, since it is unnecessary to acquire a special device to prepare the microcapsules. Generally, low-price devices for producing cells encapsulated in alginate can cost at least five times more than the amount spent for the device outlined in this study.…”

Section: Discussionmentioning

confidence: 89%

“…Matrices of different polysaccharides, such as calcium alginate or chitosan, among others, appear to be a promising alternative for improving drug delivery (Janes et al, 2001;Adinarayana et al, 2005;Kim et al, 2005), the most widely used encapsulation compound being sodium alginate (Weber et al, 2004).…”

Section: Introductionmentioning

confidence: 99%

An effective device for generating alginate microcapsules

et al. 2008

View full text Add to dashboard Cite

An alternative approach to somatic gene therapy is to deliver the therapeutic protein by implanting genetically modified cells that could overexpress the gene of interest. Microencapsulation devices were designed to protect cells from host rejection and prevent the foreign cells from spreading while allowing protein secretion. Alginate microcapsules form a semi-permeable structure that is suitable for in vivo injection. In this study, we report an effective laboratory protocol for producing calcium alginate microcapsules, following optimization of uniformly shaped and sized particles containing viable cells. Encapsulation of baby hamster kidney (BHK) cells in alginate microcapsules was performed using a simple device consisting of a cylinder of compressed air and a peristaltic pump. A cell suspension flow of 100 mL h -1 and an air jet flow of 10 L min -1 produced the best uniformity of microcapsule size and shape. Cells maintained viability in culture for 4 weeks without any signs of necrosis, and protein diffusion was observed during this period. Our results clearly demonstrated that microisolation of BHK cells in alginate using a simple assembly device could provide an environment that is capable of preserving live cells. In addition, encapsulated cells under the conditions described were able to secrete an active enzyme even after four weeks, thus becoming potentially compatible with therapeutic protein delivery.

show abstract

“…Considering these parameters, AAV-mediated transduction of rapamycin-inducible erythropoietin expression into non-human primates enabled 26 induction cycles during 6 years [25]. Microencapsulation of transgenic cell lines engineered for conditional production of therapeutic proteins into biocompatible polymers with specific protein cut-off will shield implanted cells from the host immune system while enabling free diffusion of inducer, nutrients and product proteins [93]. This technology was successfully used to control erythropoietin production in C2C12 myoblasts for up to 40 weeks in treated mice [94].…”

Section: Nucleic-acid-based Translation Fine-tuningmentioning

confidence: 99%

“…However, the cell source remains a major challenge. Suitable cells can either be autologous and isolated from the patient, transfected and selected for deficiency-complementing function and be subsequently expanded [75,114,153] prior to implantation or allogenic or xenogenic and must be shielded from the patient's immune system by microencapsulation using biocompatible polymers [93,[154][155][156]. In contrast to allogenic transplants, which become an irreversible Cell transfer Primary endothelial cells were transduced for inducible caspase-9 expression resulting in apoptosis upon rapalog administration.…”

Section: Technologies For Delivery Of Regulated Transgene Expressionmentioning

confidence: 99%

Pharmacologic transgene control systems for gene therapy

Weber

Fussenegger

2006

The Journal of Gene Medicine

Self Cite

View full text Add to dashboard Cite

Pharmacologic transgene-expression dosing is considered essential for future gene therapy scenarios. Genetic interventions require precise transcription or translation fine-tuning of therapeutic transgenes to enable their titration into the therapeutic window, to adapt them to daily changing dosing regimes of the patient, to integrate them seamlessly into the patient's transcriptome orchestra, and to terminate their expression after successful therapy. In recent years, decisive progress has been achieved in designing high-precision trigger-inducible mammalian transgene control modalities responsive to clinically licensed and inert heterologous molecules or to endogenous physiologic signals. Availability of a portfolio of compatible transcription control systems has enabled assembly of higher-order control circuitries providing simultaneous or independent control of several transgenes and the design of (semi-)synthetic gene networks, which emulate digital expression switches, regulatory transcription cascades, epigenetic expression imprinting, and cellular transcription memories. This review provides an overview of cutting-edge developments in transgene control systems, of the design of synthetic gene networks, and of the delivery of such systems for the prototype treatment of prominent human disease phenotypes.

show abstract

CellMAC: a novel technology for encapsulation of mammalian cells in cellulose sulfate/pDADMAC capsules assembled on a transient alginate/Ca2+ scaffold

Cited by 19 publications

References 40 publications

Progress technology in microencapsulation methods for cell therapy

Progress technology in microencapsulation methods for cell therapy

An effective device for generating alginate microcapsules

Pharmacologic transgene control systems for gene therapy

Contact Info

Product

Resources

About